Abstract
The thalassemia prevention programme in Sri Lanka has two main challenges; inadequacy of screening coverage due to voluntary nature of screening and doubts about the merit of the MCV and MCH as a screening test due to the possibility of missing some E beta thalassemia carriers. The screening coverage could be addressed by incorporating thalassemia screening in to the routine practice and monitoring at risk marriages at the time of registration to offer them medical counselling. Impact of missing some of the E beta thalassemia is probably over emphasised. The rare chances of inadvertent birth of a baby with E-beta thalassemia can happen only once in several years and should not thwart screening and counselling to promote safe marriages in a country.
Keywords
References
Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480–7.
Economic and social statistics of Sri Lanka, Vol. XXXVI; 2014.Available at: http://www.cbsl.gov.lk
Pemawardhena A, De Silva S, Arambepola M, et al. Thalassemia in Sri Lanka: a progress report. Hum Mol Genet. 2004;13(2):R203–6.
Olivieri NF. The beta-thalassemias. N Engl J Med. 1999;341(2):99–109.
Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med.2005;353(11):1135–46.
Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. New Engl J Med. 1993;328(9):593–602.
Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for beta-thalassaemia: a review of international practice. Eur J Hum Genet. 2010;18:1077–83.
Angantiniotis MA, Hadjiminas MG. Prevention of thalassaemia in Cyprus. Lancet. 1981;1(8216):369–71.
Samavat A, Modell B. Iranian national thalassaemia screening programme. BMJ. 2004;329(7475):1134–7.
Hesketh T. Getting married in China: pass the medical first. BMJ. 2003;326(7383):277–9.
Ginsberg G, Tulchinsky T, Filon D, et al. Cost-benefit analysis of a national thalassaemia prevention programme in Israel. J Med Screen. 1998;5(3):120–6.
Ahmadnezhad E, Sepehrvand N, Jahani FF, et al. Evaluation and cost analysis of national health policy of thalassaemia screening in west-azerbaijan province of Iran. Int J Prev Med.2012;3(10):687–92.
Nasri NW, Jamal AR, Abdullah NC, et al. Preimplantation genetic diagnosis for beta-thalassemia using single-cell DNA analysis for codons 17 and 26 of beta-globin gene. Arch Med Res.2009;40(1):1–9.
Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: WHO;1968. Available at: http://www.who.int/ bulletin/volumes/86/4/07-050112BP.pdf
Anne Andermann, Ingeborg Blancquaert, Sylvie Beauchamp, Véronique Déry. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008; 86(4):317–9.
Andermann A, Blancquaert J, Beauchamp S, De?ry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86(4):317–9.
Yeo GS, Tan KH, Liu TC. Screening for beta thalassemia and HbE traits with the mean red cell volume in pregnant women. Ann Acad Med Singapore. 1994;23(3):363–6.
de Silva S, Fisher CA, Premawardhena A, et al. Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations. Sri Lanka Thalassaemia Study Group. Lancet.
;355(9206):786–91.
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.